Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jul 3;63(6):650-4.
doi: 10.7727/wimj.2013.241. Epub 2014 May 29.

Monoclonal Antibodies in Cancer Therapy: Mechanisms, Successes and Limitations

A Coulson  1 , A Levy  1 , M Gossell-Williams  2
Affiliations

Monoclonal Antibodies in Cancer Therapy: Mechanisms, Successes and Limitations

A Coulson et al. West Indian Med J. .

Abstract
in English, Spanish

Rituximab was the first chemotherapeutic monoclonal antibody (CmAb) approved for clinical use in cancer therapeutics in 1997 and has significantly improved the clinical outcomes in non-Hodgkin's lymphoma. Since then, numerous CmAbs have been developed and approved for the treatment of various haematologic and solid human cancers. In this review, the classification, efficacy and significantly reduced toxicity of CmAbs available for use in the United States of America are presented. Finally, the limitations of CmAbs and future considerations are explored.

Rituximab fue el primer anticuerpo monoclonal quimioterapéutico (CmAb, siglas en inglés) aprobado para uso clínico en la terapia del cáncer en 1997, y ha mejorado significativamente los resultados clínicos en el linfoma no hodgkiniano. Desde entonces, numerosos CmAbs han sido elaborados y aprobados para el tratamiento de varios cánceres humanos sólidos y hematológicos. En esta revisión, se presentan la clasificación, la eficacia y la toxicidad significativamente reducida de los CmAbs disponibles para su uso en los Estados Unidos de América. Finalmente, se exploran las limitaciones de los CmAbs y futuras consideraciones.

PubMed Disclaimer

References

    1. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495–497. - PubMed
    1. Yoon S, Kim YS, Shim H, Chung J. Current perspectives on therapeutic antibodies. Biotechnol Bioprocess Eng. 2010;15:709–715.
    1. Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 2010;9:325–338. - PubMed
    1. Seimetz D. Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (removab) J Cancer. 2011;2:309–309. - PMC - PubMed
    1. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol. 2005;23:1073–1078. - PubMed

LinkOut - more resources